The effect of salmeterol on human eosinophils is both stimulus- and response-dependent.
Salmeterol, a long-acting beta 2-adrenoceptor agonist, also possesses some anti-inflammatory properties, but whether eosinophils are the target of such action has been equivocal. To clarify the direct effect of salmeterol on eosinophil functions, we have studied the effect of the drug on the various responses of purified human eosinophils. Superoxide anions (O2-) release and adherence to fibronectin-coated plastic plates induced by platelet-activating factor (PAF), interleukin-5 (IL-5), leukotriene B4 (LTB4) and phorbol myristate acetate (PMA), as well as degranulation induced by C5a and formyl methionyl leucyl phenylalanine (FMLP), in the presence of cytochalasin B (CB) were studied. In the concentration range 10(-8)-10(-5) M, the drug inhibited PAF- and IL-5-induced O2- release, with an IC50 values of 3.2 +/- 1.2 x 10(-7) M and 2.2 +/- 0.4 x 10(-6) M, respectively, Superoxide anion release by LTB4 was only modestly inhibited while that due to PMA was completely unaffected. On the other hand, eosinophil adherence induced by all the 4 stimuli were significantly inhibited within the same concentration range. On eosinophil degranulation, the drug failed to significantly inhibit the release of eosinophil peroxidase (EPO) induced by either C5a or FMLP. In contrast, beta-hexoseaminidase (beta-HA) release by the same agents was significantly inhibited, the inhibition being more pronounced for FMLP-induced, than C5a-induced release. None of the effects of the drug was reversed by the selective beta 2-adrenoceptor antagonist ICI 118551 at a concentration of 10(-7) M. These results show that salmeterol may have some direct inhibitory effects on human eosinophil functions but that these effects are both stimulus- and response-dependent, and are unlikely to be mediated via beta 2 adrenoceptors.
Ezeamuzie
C I
CI
Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Kuwait.
al-Hage
M
M
Nwankwoala
R N
RN
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D047209:Eosinophil Peroxidase; D004804:Eosinophils / Q000187:drug effects* / Q000502:physiology; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D015848:Interleukin-5 / Q000494:pharmacology; D007975:Leukotriene B4 / Q000494:pharmacology; D010544:Peroxidases / Q000378:metabolism; D010972:Platelet Activating Factor / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology; D000068299:Salmeterol Xinafoate; D013481:Superoxides / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D001619:beta-N-Acetylhexosaminidases / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D005353:Fibronectins; D015848:Interleukin-5; D010972:Platelet Activating Factor; D011412:Propanolamines; D013481:Superoxides; D007975:Leukotriene B4; C026777:ICI 118551; D000068299:Salmeterol Xinafoate; D047209:Eosinophil Peroxidase; D010544:Peroxidases; D001619:beta-N-Acetylhexosaminidases; D013755:Tetradecanoylphorbol Acetate; D000420:Albuterol